$VNRX
VolitionRX Ltd Stock $vnrx

$vnrx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147793224001453 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$171.5K	$244.0K	$775.3K
YoY Change	14.5%	103.78%	153.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.927M	$4.369M	$16.92M
YoY Change	-8.45%	4.38%	-3.39%
% of Gross Profit
Research & Development	$4.630M	$4.252M	$18.43M
YoY Change	-5.63%	16.93%	26.48%
% of Gross Profit
Depreciation & Amortization	$277.5K	$292.5K	$1.153M
YoY Change	10.62%	17.5%	33.2%
% of Gross Profit
Operating Expenses	$8.556M	$8.985M	$36.76M
YoY Change	-6.95%	10.51%	14.57%
Operating Profit	-$8.385M		-$35.99M
YoY Change	-7.3%		13.24%
Interest Expense	-$68.58K	-$49.66K	-$128.3K
YoY Change	-1183.41%	-600.1%	168.3%
% of Operating Profit
Other Income/Expense, Net	-$87.50K	-$9.530K	$454.8K
YoY Change	-150.84%	-101.43%	-63.01%
Pretax Income	-$8.472M	-$8.800M	-$35.68M
YoY Change	-4.52%	19.95%	16.6%
Income Tax
% Of Pretax Income
Net Earnings	-$8.472M	-$8.698M	-$35.32M
YoY Change	-3.5%	20.11%	15.43%
Net Earnings / Revenue	-4938.94%	-3565.29%	-4555.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.10	-$0.11	-$0.50
COMMON SHARES
Basic Shares Outstanding	82.07M shares	78.69M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.77M	$20.73M	$20.73M
YoY Change	17.59%	90.76%	90.76%
Cash & Equivalents	$11.77M	$20.73M	$20.73M
Short-Term Investments
Other Short-Term Assets	$470.1K	$881.5K	$881.5K
YoY Change	-34.43%	96.95%	-28.48%
Inventory
Prepaid Expenses	$1.094M	$521.4K
Receivables	$133.5K	$242.6K	$242.6K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.47M	$21.85M	$21.85M
YoY Change	12.65%	79.54%	79.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.181M	$6.073M	$6.073M
YoY Change	-4.1%	12.6%	1.0%
Goodwill
YoY Change
Intangibles	$215.1K	$23.89K
YoY Change	136.85%	-78.38%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.965M	$6.096M	$6.096M
YoY Change	-1.99%	-0.43%	-0.43%
TOTAL ASSETS
Total Short-Term Assets	$13.47M	$21.85M	$21.85M
Total Long-Term Assets	$5.965M	$6.096M	$6.096M
Total Assets	$19.43M	$27.95M	$27.95M
YoY Change	7.71%	52.78%	52.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.528M	$3.211M	$3.211M
YoY Change	18.0%	5.53%	5.53%
Accrued Expenses	$3.305M	$4.128M	$4.128M
YoY Change	21.56%	43.72%	32.42%
Deferred Revenue		$126.6K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.150M	$1.311M	$1.311M
YoY Change	2.58%	22.94%	13.59%
Total Short-Term Liabilities	$31.49M	$31.84M	$31.84M
YoY Change	82.69%	83.12%	83.12%
LONG-TERM LIABILITIES
Long-Term Debt	$3.373M	$4.448M	$4.448M
YoY Change	32.3%	60.03%	22.33%
Other Long-Term Liabilities	$396.4K	$378.1K	$378.1K
YoY Change	3.84%	-5.51%	-5.51%
Total Long-Term Liabilities	$4.563M	$4.826M	$4.826M
YoY Change	78.99%	73.63%	19.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.49M	$31.84M	$31.84M
Total Long-Term Liabilities	$4.563M	$4.826M	$4.826M
Total Liabilities	$36.05M	$35.75M	$35.75M
YoY Change	71.49%	66.9%	71.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$210.9M	-$202.6M
YoY Change	19.83%	21.12%
Common Stock	$82.11K	$81.90K
YoY Change	30.1%	41.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$15.61M	-$7.802M	-$7.802M
YoY Change
Total Liabilities & Shareholders Equity	$19.43M	$27.95M	$27.95M
YoY Change	7.71%	52.78%	52.78%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$8.472M	-$8.698M	-$35.32M
YoY Change	-3.5%	20.11%	15.43%
Depreciation, Depletion And Amortization	$277.5K	$292.5K	$1.153M
YoY Change	10.62%	17.5%	33.2%
Cash From Operating Activities	-$8.342M	$6.447M	-$18.06M
YoY Change	-4.6%	-224.38%	18.23%
INVESTING ACTIVITIES
Capital Expenditures	$28.81K	$303.7K	$1.084M
YoY Change	-85.64%	-47.52%	-30.98%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$78.81K	-$303.7K	-$1.084M
YoY Change	-60.71%	-47.52%	-30.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$28.36M
YoY Change			320.94%
Debt Paid & Issued, Net	$210.2K		$981.3K
YoY Change	-5.89%		-22.63%
Cash From Financing Activities	-$209.4K	3.773M	28.98M
YoY Change	-102.57%	1135.29%	317.74%
NET CHANGE
Cash From Operating Activities	-$8.342M	6.447M	-18.06M
Cash From Investing Activities	-$78.81K	-303.7K	-1.084M
Cash From Financing Activities	-$209.4K	3.773M	28.98M
Net Change In Cash	-$8.958M	9.916M	9.836M
YoY Change	946.26%	-281.73%	-201.25%
FREE CASH FLOW
Cash From Operating Activities	-$8.342M	$6.447M	-$18.06M
Capital Expenditures	$28.81K	$303.7K	$1.084M
Free Cash Flow	-$8.371M	$6.143M	-$19.15M
YoY Change	-6.42%	-206.62%	13.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7802255	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-909967	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-551971	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8712222	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3126962	usd
CY2023	vnrx	Service Revenue ServiceRevenue	175476	usd
CY2022	vnrx	Service Revenue ServiceRevenue	92488	usd
CY2022	vnrx	Product Revenue ProductRevenue	210993	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2872247	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10867050	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72609	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	784920	usd
CY2022Q4	us-gaap	Management Fee Payable ManagementFeePayable	71119	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	48570	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	199323	usd
CY2023Q4	us-gaap	Liabilities Liabilities	36662720	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	81898	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	57873	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	194448414	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164397468	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	243940	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-202576507	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167257429	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27950498	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18295054	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	227097	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2574991	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	110505	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1066700	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17386087	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	436132	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	400091	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000093314
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81898321	shares
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	23000000.0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	vnrx	Common Stock Price Per Sahres CommonStockPricePerSahres	0.001
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36833
CY2023	dei	Entity Registrant Name EntityRegistrantName	VOLITIONRX LIMITED
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1949078
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1489 West Warm Springs Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89014
CY2023	dei	City Area Code CityAreaCode	646
CY2023	dei	Local Phone Number LocalPhoneNumber	650–1351
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	VNRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	82181507	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82068442	shares
CY2023	dei	Auditor Firm AuditorFirmId	3627
CY2023	dei	Auditor Name AuditorName	Sadler, Gibb & Associates, LLC
CY2023	dei	Auditor Location AuditorLocation	Draper, UT
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	447566	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12172145	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5393012	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	619392	usd
CY2022Q4	us-gaap	Assets Assets	18295054	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3043008	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	126649	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	46014	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245163	usd
CY2023Q4	vnrx	Grant Repayable Current GrantRepayableCurrent	55855	usd
CY2022Q4	vnrx	Grant Repayable Current GrantRepayableCurrent	41836	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2779240	usd
CY2022Q4	vnrx	Grant Repayable Non Current GrantRepayableNonCurrent	420466	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81898321	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57873379	shares
CY2023	vnrx	Royalty Revenue RoyaltyRevenue	1369	usd
CY2022	vnrx	Royalty Revenue RoyaltyRevenue	2911	usd
CY2023	vnrx	Product Revenue ProductRevenue	598457	usd
CY2023	us-gaap	Revenues Revenues	775302	usd
CY2022	us-gaap	Revenues Revenues	306392	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19551523	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15332989	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10368314	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10177229	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6843160	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6576246	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	36762997	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	32086464	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-35987695	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-31780072	usd
CY2023	vnrx	Income From Grants IncomeFromGrants	214451	usd
CY2022	vnrx	Income From Grants IncomeFromGrants	1229425	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-15843	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	93324	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	125265	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	221622	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	173087	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	240311	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	310621	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1181603	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35677074	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-30598469	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	357996	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	329676	usd
CY2023	vnrx	Net Gain Loss Attributable To Volitionrx Limited Stockholders NetGainLossAttributableToVolitionrxLimitedStockholders	-35319078	usd
CY2022	vnrx	Net Gain Loss Attributable To Volitionrx Limited Stockholders NetGainLossAttributableToVolitionrxLimitedStockholders	-30268793	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	16843	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	78771	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35660231	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30519698	usd
CY2023	vnrx	Earnings Per Share Basic And Diluted Attributable To Shareholders EarningsPerShareBasicAndDilutedAttributableToShareholders	-0.50
CY2022	vnrx	Earnings Per Share Basic And Diluted Attributable To Shareholders EarningsPerShareBasicAndDilutedAttributableToShareholders	-0.55
CY2023	vnrx	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	71234565	shares
CY2022	vnrx	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	55350401	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17722105	usd
CY2022	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6736444	usd
CY2022	vnrx	Tax Withholdings Paid Related To Stock Based Compensation TaxWithholdingsPaidRelatedToStockBasedCompensation	-180472	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3114659	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	78771	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-30598469	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3126962	usd
CY2023	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2023	vnrx	Common Stock Issued For Cash Net Of Issuance Costs And Allocation To Warrant Liability Amount CommonStockIssuedForCashNetOfIssuanceCostsAndAllocationToWarrantLiabilityAmount	28021076	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	-31772	usd
CY2023	vnrx	Tax Withholdings Paid Related To Stock Based Compensation TaxWithholdingsPaidRelatedToStockBasedCompensation	-203878	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2289545	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16843	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35677074	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8712222	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35677074	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-30598469	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1152534	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	936084	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	260743	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	253864	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-15843	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2289545	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3114659	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	240311	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-169666	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-72609	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	263550	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	433995	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	87441	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	351514	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1224743	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	548611	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	13000000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9987488	usd
CY2023	vnrx	Increase Decrease In Management And Directors Fees Payable IncreaseDecreaseInManagementAndDirectorsFeesPayable	-11494	usd
CY2022	vnrx	Increase Decrease In Management And Directors Fees Payable IncreaseDecreaseInManagementAndDirectorsFeesPayable	-184	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-258853	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-232695	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18062999	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15277742	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1083749	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1570182	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1083749	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1570182	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28388036	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6736444	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	203878	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	180472	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	31772	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	vnrx	Proceeds From Grants Repayable ProceedsFromGrantsRepayable	25315	usd
CY2022	vnrx	Proceeds From Grants Repayable ProceedsFromGrantsRepayable	218445	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1854877	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1523098	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	981291	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1268386	usd
CY2023	vnrx	Payments On Grants Repayable PaymentsOnGrantsRepayable	22096	usd
CY2022	vnrx	Payments On Grants Repayable PaymentsOnGrantsRepayable	45664	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	46506	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	45433	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28982685	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6938032	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26996	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195629	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9862933	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9714263	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10867050	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20581313	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20729983	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10867050	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	221622	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	173110	usd
CY2023	vnrx	Stock Issued During Period Shares Setttlement Of Vested Restricted Stock Units StockIssuedDuringPeriodSharesSetttlementOfVestedRestrictedStockUnits	658	usd
CY2022	vnrx	Stock Issued During Period Shares Setttlement Of Vested Restricted Stock Units StockIssuedDuringPeriodSharesSetttlementOfVestedRestrictedStockUnits	297	usd
CY2023	vnrx	Offering Costs From Issuance Of Common Stock OfferingCostsFromIssuanceOfCommonStock	392822	usd
CY2022	vnrx	Offering Costs From Issuance Of Common Stock OfferingCostsFromIssuanceOfCommonStock	427443	usd
CY2023	vnrx	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	366960	usd
CY2022	vnrx	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	0	usd
CY2023	vnrx	Non Cash Note Payable NonCashNotePayable	356258	usd
CY2022	vnrx	Non Cash Note Payable NonCashNotePayable	620549	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Note 1 – Organization and Nature of Operations </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company was incorporated under the laws of the State of Delaware on September 24, 1998. On September 22, 2011, the Company filed a Certificate for Renewal and Revival of Charter with the Secretary of State of Delaware. Pursuant to Section 312(1) of the Delaware General Corporation Law, the Company was revived under the new name of “VolitionRX Limited” and the name change became effective on October 11, 2011. On October 7, 2016, the Company amended its Certificate of Incorporation to reflect a name change to “VolitionRx Limited.”</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 6, 2011, the Company entered into a share exchange agreement with Singapore Volition Pte. Limited, a Singapore corporation incorporated on August 5, 2010 (“Singapore Volition”), and the shareholders of Singapore Volition. Pursuant to the terms of the share exchange agreement, the former shareholders of Singapore Volition held 85% of the issued and outstanding common shares of the Company. The issuance was deemed to be a reverse acquisition for accounting purposes and as such, Singapore Volition is regarded as the predecessor of the Company. The number of shares outstanding and per share amounts of the Company have been restated to recognize the foregoing recapitalization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company’s principal business objective through its subsidiaries is to develop and bring to market simple, easy to use, cost effective blood tests designed to help diagnose and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics<sup style="vertical-align:super">TM</sup>, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. The Company has two wholly owned subsidiaries, Volition Global Services SRL (“Volition Global”) which was formed in August 2021 and Singapore Volition. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL, a Belgium private limited liability company (“Belgian Volition”), which it acquired in September 2010. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (“Volition Diagnostics”), which was formed in November 2015, Volition America, Inc. (“Volition America”), which was formed in February 2017, Volition Germany GmbH (“Volition Germany”), which was acquired in January 2020, as well as its majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (“Volition Vet”), which was formed in June 2019. Following the acquisition of Singapore Volition in 2011, the Company’s fiscal year end was changed from August 31 to December 31.</p>
CY2023	vnrx	Fair Value Of Warrant Liability Issuance FairValueOfWarrantLiabilityIssuance	366960	usd
CY2023	vnrx	Net Income Loss Since Inception NetIncomeLossSinceInception	202600000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.</p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20729983	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10867050	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	15220237	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	7925876	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	242617	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	243940	usd
CY2023Q4	vnrx	Warrant Liability WarrantLiability	126649	usd
CY2022Q4	vnrx	Warrant Liability WarrantLiability	0	usd
CY2023	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	-240311	usd
CY2023Q4	vnrx	Warrant Liability WarrantLiability	126649	usd
CY2023	vnrx	Terms Of License Agreement TermsOfLicenseAgreement	Belgian Volition entered into a Master License and Supply Agreement (the “License Agreement”) with Heska Corporation (“Heska”), a leading global provider of advanced veterinary diagnostics, pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q® Vet Cancer Test at the point of care (“POC”) initially for the screening of lymphoma and hemangiosarcoma in dogs (“Canine Lymphoma & HSA”), and non-exclusive rights to sell its Nu.Q® Vet Cancer Test in kit format (“Kits”) through Heska’s network of central reference laboratories (“Central Lab”) initially for Canine Lymphoma & HSA
CY2023	vnrx	Initial Term For Poc InitialTermForPoc	P22Y
CY2023	vnrx	Initial Term For Central Lab InitialTermForCentralLab	P5Y
CY2022	vnrx	Upfront Payment UpfrontPayment	10000000.0	usd
CY2023	vnrx	Upfront Payment UpfrontPayment	13000000.0	usd
CY2023	vnrx	Milestone Amount Recognized MilestoneAmountRecognized	28000000.0	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	19600000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	15300000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Certain reclassifications within operating expenses have been made to prior period’s consolidated financial statements to conform to the current period financial statement presentation. There is no impact in total to the results of operations and cash flows in all periods presented.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Financial instruments that potentially subject the company to concentration of credit risk consist primarily of accounts receivable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses. Management does not believe significant credit risks exist at December 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As at December 31, 2023 the two largest customer balances represented over 65% of the total outstanding accounts receivable balance.</p>
CY2023	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.65	pure
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9712102	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4189089	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5523013	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8705875	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3312863	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5393012	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1100000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1600000	usd
CY2023	us-gaap	Depreciation Depreciation	1080475	usd
CY2022	us-gaap	Depreciation Depreciation	865262	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	84910	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75558	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	23886	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23886	usd
CY2023Q4	vnrx	Common Stock Share Authorized CommonStockShareAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81898321	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57873379	shares
CY2023	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodRiskFreeInterestRate	0.0389	pure
CY2023Q2	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodRiskFreeInterestRate	0.0370	pure
CY2023	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedVolatilityRate	0.7630	pure
CY2023Q2	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedVolatilityRate	0.7156	pure
CY2023	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedTerm1	P4Y5M8D
CY2023Q2	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedTerm1	P5Y10D
CY2023	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedDividendRate	0	pure
CY2023Q2	vnrx	Share Based Goods And Nonemployee Service Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServiceTransactionValuationMethodExpectedDividendRate	0	pure
CY2023	vnrx	Total Fair Value Of Warrants TotalFairValueOfWarrants	126649	usd
CY2023Q2	vnrx	Total Fair Value Of Warrants TotalFairValueOfWarrants	366960	usd
CY2023	vnrx	Stock Options Granted Shares StockOptionsGrantedShares	285536	shares
CY2023	vnrx	Stockoptions Cancelled StockoptionsCancelled	285536	shares
CY2023	vnrx	Equity Incentive Rsu EquityIncentiveRsu	836828	shares
CY2023	vnrx	Incentive Rsu Issued IncentiveRsuIssued	658102	shares
CY2023	vnrx	Rsus Held For Taxes RsusHeldForTaxes	178726	usd
CY2022	vnrx	Equity Incentive Rsu EquityIncentiveRsu	377007	shares
CY2022	vnrx	Incentive Rsu Issued IncentiveRsuIssued	297289	shares
CY2022	vnrx	Rsus Held For Taxes RsusHeldForTaxes	79718	usd
CY2023	vnrx	Common Stock Expired Unexercised Shares CommonStockExpiredUnexercisedShares	125000	shares
CY2022Q2	vnrx	Common Stock Available CommonStockAvailable	1750000	shares
CY2022Q2	vnrx	Share Aggregate Maximum ShareAggregateMaximum	7750000	shares
CY2023Q2	vnrx	Common Stock Available CommonStockAvailable	1950000	shares
CY2023Q2	vnrx	Share Aggregate Maximum ShareAggregateMaximum	9700000	shares
CY2023	vnrx	Stock Options Cancelled StockOptionsCancelled	285536	shares
CY2023	vnrx	Approved Stock Options ApprovedStockOptions	285536	shares
CY2022	vnrx	Approved Stock Options ApprovedStockOptions	42413	shares
CY2022	vnrx	Stock Options Cancelled StockOptionsCancelled	42413	shares
CY2023Q4	vnrx	Long Term Debt Payable LongTermDebtPayable	4831867	usd
CY2023	vnrx	Compensation Expense Rsus CompensationExpenseRsus	2317882	shares
CY2022	vnrx	Compensation Expense Rsus CompensationExpenseRsus	1828216	shares
CY2023	vnrx	Rsu Expense RsuExpense	1892102	usd
CY2022	vnrx	Rsu Expense RsuExpense	2755843	usd
CY2023	vnrx	Equity Incentive Rsu EquityIncentiveRsu	836828	shares
CY2023	vnrx	Incentive Rsu Issued IncentiveRsuIssued	658102	shares
CY2023	vnrx	Rsus Held For Taxes RsusHeldForTaxes	178726	usd
CY2022	vnrx	Equity Incentive Rsu EquityIncentiveRsu	377007	shares
CY2022	vnrx	Incentive Rsu Issued IncentiveRsuIssued	297289	shares
CY2022	vnrx	Rsus Held For Taxes RsusHeldForTaxes	79718	usd
CY2023	vnrx	Incentive Rsu IncentiveRsu	109010	shares
CY2023	vnrx	Rsu Cancelled RsuCancelled	109010	shares
CY2022	vnrx	Incentive Rsu IncentiveRsu	62937	shares
CY2022	vnrx	Rsu Cancelled RsuCancelled	62937	shares
CY2023Q4	vnrx	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	33370	usd
CY2023Q4	vnrx	Operating Leases Future Minimum Lease Payment Due OperatingLeasesFutureMinimumLeasePaymentDue	33370	usd
CY2023	vnrx	Grant Repyable GrantRepyable	478562	usd
CY2023	vnrx	Operatings Income Loss OperatingsIncomeLoss	33100000	usd
CY2022	vnrx	Operatings Income Loss OperatingsIncomeLoss	28600000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.033	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.008	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.003	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	-0.002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Foreign EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign	-0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.005	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.175	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.212	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q4	vnrx	Increase In Valuation Allowance IncreaseInValuationAllowance	6265160	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1481023	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	922911	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	692557	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	452470	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1918778	usd
CY2023Q4	us-gaap	Long Term Debt Maturing In Years Four And Five LongTermDebtMaturingInYearsFourAndFive	323802	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	5791541	usd
CY2023Q4	vnrx	Long Term Debt Less Amount Representing Interest LongTermDebtLessAmountRepresentingInterest	959674	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	4831867	usd
CY2023Q4	vnrx	Payments For Future Research And Collobration PaymentsForFutureResearchAndCollobration	1273692	usd
CY2023Q4	vnrx	Future Minimum Collaborative Agreement Obligations Of Fiscal Year Four FutureMinimumCollaborativeAgreementObligationsOfFiscalYearFour	1110146	usd
CY2023Q4	vnrx	Future Minimum Collaborative Agreement Obligations Of Fiscal Yearfive FutureMinimumCollaborativeAgreementObligationsOfFiscalYearfive	163546	usd
CY2023Q4	vnrx	Collaborative Agreement Obligations CollaborativeAgreementObligations	1273692	usd
CY2020Q4	vnrx	Aggerate Amount Payable Description AggerateAmountPayableDescription	under this agreement will be completed by the end of the first quarter 2024 at a total cost to the Company of up to $4.2 million
CY2023	vnrx	Amount Payable For Services Rendered AmountPayableForServicesRendered	90862	usd
CY2023Q4	vnrx	Amount May Be Payable By Company In Future Periods For Services Rendered AmountMayBePayableByCompanyInFuturePeriodsForServicesRendered	208320	usd
CY2023	vnrx	Recognized Compensation Expense RecognizedCompensationExpense	901410	usd
CY2023	vnrx	Schedule Of Outcomes Related To The Prescribed Performance Targets ScheduleOfOutcomesRelatedToThePrescribedPerformanceTargets	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:60%"><tbody><tr style="height:15px"><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total </strong></p></td><td style="width:1%;"></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amortized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amortized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amortized</strong></p></td><td style="width:1%;"></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Un-Amortized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Award</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>$</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><strong>$</strong> </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><strong>$</strong></td><td style="white-space: nowrap;"></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><strong>$</strong></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><strong>$</strong></td><td style="white-space: nowrap;"></td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">969,593</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">580,412</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">389,181</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">901,410 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">270,547</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">450,090</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">180,773</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:60%"><tbody><tr style="height:15px"><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amortized</strong></p></td><td style="width:1%;"></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amortized</strong></p></td><td style="width:1%;"></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amortized</strong></p></td><td style="width:1%;"></td><td class="hdcell" style="width:12%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Un-Amortized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Award</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2021</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>$</strong> </p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>$</strong></p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>$</strong> </p></td><td></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>$</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">822,149</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">493,207</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">328,942</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">759,039</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">228,109</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">379,191</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">151,739</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr></tbody></table>
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1077417	usd
CY2023Q4	vnrx	Accrued Compensation Expense AccruedCompensationExpense	1071198	usd
CY2023	us-gaap	Officers Compensation OfficersCompensation	1100000	usd

Files In Submission

Name	View Source	Status
0001477932-24-001453-index-headers.html	Edgar Link	pending
0001477932-24-001453-index.html	Edgar Link	pending
0001477932-24-001453.txt	Edgar Link	pending
0001477932-24-001453-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vnrx-20231231.xsd	Edgar Link	pending
vnrx_10k.htm	Edgar Link	pending
vnrx_10kimg1.jpg	Edgar Link	pending
vnrx_ex1036.htm	Edgar Link	pending
vnrx_ex1036img2.jpg	Edgar Link	pending
vnrx_ex211.htm	Edgar Link	pending
vnrx_ex231.htm	Edgar Link	pending
vnrx_ex311.htm	Edgar Link	pending
vnrx_ex312.htm	Edgar Link	pending
vnrx_ex321.htm	Edgar Link	pending
vnrx_ex971.htm	Edgar Link	pending
vnrx-20231231_def.xml	Edgar Link	unprocessable
vnrx-20231231_lab.xml	Edgar Link	unprocessable
vnrx-20231231_pre.xml	Edgar Link	unprocessable
vnrx_10k_htm.xml	Edgar Link	completed
vnrx-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VNRX
VolitionRX Ltd Stock $vnrx

2024 Q1 Form 10-K Financial Statement

#000147793224001453 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNRX VolitionRX Ltd Stock $vnrx

2024 Q1 Form 10-K Financial Statement

#000147793224001453 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNRX
VolitionRX Ltd Stock $vnrx